If the company was actually analysed by institutions or other analysts I think it would go up on its fundamentals. It has a genuine revenue stream and a new product that will increase that substantially. It is currently way undervalued.
However, i agree it will not go up until either the next quarterly OR a news release on developments in Hepafat or the fibrosis scan.
very low volume, page-14
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $24.57M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 116743 | 2 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| RHT (ASX) Chart |
Day chart unavailable